Company intelligence / Profile preview

Bottneuro

Basel, Basel-Stadt, Switzerlandbottneuro.ch ↗

Ownership: Private
Development stage: Other

Overview

Bottneuro has developed a fully personalized neurostimulation therapy platform based on each patient's MRI data. Their non-invasive tES/tCS/EEG device enables targeted electrical stimulation of specific brain regions implicated in neurological diseases. The first human study has been completed and the company has begun treating initial patients in Switzerland. The device can be prescribed for Alzheimer's disease and other neurological conditions under Custom Made Device regulations in Switzerland, the UK, and EU.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Positrigo (for PET imaging technology to localize treatment targets)

Beyond the preview

Go deeper on Bottneuro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bottneuro.

Explore the full profile